RaySearch Laboratories AB (STO:RAY.B), a provider of software for radiation therapy, announced on Friday that it has secured an order worth DKK10.5m (approximately SEK15.4m) from Odense University Hospital, part of the South Denmark Region, for its RayStation treatment planning system.
Odense University Hospital's radiotherapy centre, a leader in automated treatment planning, aims to further expand automation across the entire planning process, from initial assessments to finalised treatment plans. RayStation was selected following an extensive market evaluation focused on supporting continued innovation in automation.
RayStation integrates both machine learning and traditional planning algorithms. Its upcoming version will feature a new auto-optimisation algorithm, currently under development in collaboration with Memorial Sloan Kettering Cancer Center.
Most of the revenue from the order is expected to be recognized in the first quarter of 2025. The agreement excludes a service contract and remains subject to regulatory clearance in certain markets.
(USD1.00 = DKK6.57)
Sino Biological launches 2026-2027 Northern Hemisphere influenza vaccine strain antigens
Esperion to acquire Corstasis, expanding cardiovascular portfolio
Breckenridge Pharmaceutical launches Pomalidomide Capsules in US market
Genentech's fenebrutinib meets primary endpoint in pivotal Phase III study for multiple sclerosis
ValiRx establishes animal health subsidiary to target veterinary oncology market
Novacyt completes acquisition of Southern Cross Diagnostics
Gemma Biotherapeutics doses first parent in GB221 Phase 1/2 CHARISMA clinical trial
Circio reports up to 50-fold gene expression gain in eye for circVec-AAV platform
Melodia Therapeutics reports award of US patent covering MLD-151
Argo Biopharmaceutical to present BW-20805 Phase II interim data at AAAAI 2026 Annual Meeting
Novartis to build new radioligand therapy site in Texas
GSK to acquire 35Pharma for USD950m to strengthen cardiopulmonary pipeline
Epredia signs EU distribution deal with Mindpeak for AI pathology software
Armata Pharmaceuticals' AP-SA02 receives QIDP designation from US FDA